Briciclib sodium

Overview

Briciclib (ON 014185) sodium is a eukaryotic translation initiation factor 4E ( eIF4E ) inhibitor. Briciclib sodium exhibits broad-spectrum anti-cancer activity, including in mantle cell leukemia, breast cancer , gastric cancer , and esophageal cancer cells. Briciclib sodium reduces the expression of cyclin D1 and c-Myc , and enhances the expression of P53 and Cleaved Caspase 3 pro- apoptotic proteins. Briciclib sodium can be used for the study of hematological system tumors and solid tumors.

Application

Products | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Eukaryotic Initiation Factor (eIF) | Products > Signaling Pathways > CDK | Products > Signaling Pathways > c-Myc | Products > Signaling Pathways > MDM-2/p53 | Products > Signaling Pathways > Caspase | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-16366A
• CAS No.: 865784-01-6
• Molecular Formula: C19H21Na2O10PS
• Molecular Weight: 518.38
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source